Cover Image

Treatment of heart failure with preserved ejection fraction

Alfredo Monteverde, Valeria Carlino, Giulia Ganci, Giuseppe Taormina, Mario Barbagallo
  • Alfredo Monteverde
    University Hospital “Paolo Giaccone”, Department of emerging diseases and of continuity of care, Italy | alfredo.monteverde14@gmail.com
  • Valeria Carlino
    University Hospital “Paolo Giaccone”, Department of emerging diseases and of continuity of care, Italy
  • Giulia Ganci
    Agency for Health Care 5 “Friuli Occidentale”, Cardiology Unit, Italy
  • Giuseppe Taormina
    University Hospital “Paolo Giaccone”, Department of emerging diseases and of continuity of care, Italy
  • Mario Barbagallo
    University Hospital “Paolo Giaccone”, Department of emerging diseases and of continuity of care, Italy

Abstract

Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clinical congestion (IB). Studies carried out with ACE-inhibitor (or angiotensin-receptor antagonist) or beta-blocker or anti-aldosterone to evaluate their efficacy also in HFpEF have substantially shown a benefit only on a reduction in the hospitalization rate. The same guidelines identify regular aerobic activity (IA) as more effective in the condition of HFpEF and indicate, appropriately, the need to treat comorbidities (IC) in the elderly (where they are more present and more numerous). They also recommend to avoid certain associations of drugs and, obviously, harmful (and contraindicated) medications that could worsen the clinical picture or might be potentially lethal.

Keywords

Ejection fraction; heart failure; comorbidity; guidelines; therapeutic strategies.

Full Text:

PDF
Submitted: 2018-04-24 12:40:32
Published: 2018-06-07 14:54:28
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
2433

Views:
PDF
94

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2018 Alfredo Monteverde, Valeria Carlino, Giulia Ganci, Giuseppe Taormina, Mario Barbagallo

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy